NDAOPHTHALMICGEL
Approved
Oct 2008
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
5/8 — Partial
Drug data last refreshed 8h ago · AI intelligence enriched 11h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTEN is a topical ophthalmic gel formulation of lidocaine hydrochloride anhydrous approved in 2008 for use in eye procedures requiring local anesthesia. It is a small-molecule local anesthetic that works by blocking sodium channels in nerve fibers, providing rapid onset pain relief. The product is indicated for corneal anesthesia during diagnostic and therapeutic ophthalmic procedures.
$0.001BPart D
Post-LOEStable
Post-LOEMinimal commercial activity with only 14 Part D claims in 2023 indicates a niche, mature product with likely small team structures focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Thea Pharma is hiring 2 roles related to this product
Worked on AKTEN at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.